{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:30:42Z","timestamp":1794328242601,"version":"4.9.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.biopha.2024.117709","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:43:57Z","timestamp":1732517037000},"page":"117709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"181","author":[{"given":"Kotaro","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-9571","authenticated-orcid":false,"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-6938","authenticated-orcid":false,"given":"Miho","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Toyozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5405","key":"10.1016\/j.biopha.2024.117709_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.biopha.2024.117709_bib2","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117709_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","article-title":"Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance","volume":"38","author":"Claudiani","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2024.117709_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7150\/ijbs.86305","article-title":"Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Sun","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2024.117709_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of human ABCG2: from technical background to recent updates with clinical implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117709_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bdd.2022","article-title":"TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux","volume":"37","author":"Cunha","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"issue":"1-2","key":"10.1016\/j.biopha.2024.117709_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2012.01.005","article-title":"Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance","volume":"15","author":"Shukla","year":"2012","journal-title":"Drug Resist Updat"},{"issue":"10","key":"10.1016\/j.biopha.2024.117709_bib8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.18632\/oncotarget.1050","article-title":"High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients","volume":"4","author":"Delord","year":"2013","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2024.117709_bib9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117709_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56900-2","article-title":"Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein","volume":"9","author":"Ikemura","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117709_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117709_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12185-020-03000-x","article-title":"The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration","volume":"113","author":"Ito","year":"2021","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117709_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.biopha.2024.117709_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121928","article-title":"Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma","volume":"1137","author":"Mukai","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.117709_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.biopha.2024.117709_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2017.10.004","article-title":"BCRP\/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications","volume":"147","author":"Hira","year":"2018","journal-title":"Biochem. Pharmacol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224015956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224015956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:58:31Z","timestamp":1787921911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224015956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":16,"alternative-id":["S0753332224015956"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117709","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117709"}}